View Older Stories View More Recent Stories

Feb 25, 2020 10:15AM U.S. health officials urge Americans to prepare for spread of coronavirus
Feb 19, 2020 08:30AM Gilead Appoints Michael Quigley to Lead Research Biology Group and Names Linda Higgins as Head of Company’s External Innovation Center
Feb 18, 2020 08:00PM Gilead Sciences to Present at the Cowen and Company 40th Annual Health Care Conference on Monday, March 2, 2020
Feb 10, 2020 08:33AM Gilead Sciences (GILD) Announces FDA Grants Priority Review for Kite's KTE-X19 BLA in R/R Mantle Cell Lymphoma
Feb 10, 2020 08:30AM U.S. FDA Grants Priority Review for Kite’s KTE-X19 Biologics License Application (BLA) in Relapsed or Refractory Mantle Cell Lymphoma
Feb 4, 2020 04:02PM Gilead Sciences Announces 8 Percent Increase In First Quarter 2020 Dividend
Jan 30, 2020 04:05PM Sandra Horning, MD, Joins Gilead Sciences’ Board of Directors
Jan 28, 2020 04:15PM European Medicines Agency Validates Kite’s Marketing Application for Company’s Second CAR T Cell Therapy
Jan 21, 2020 05:30PM Gilead Sciences to Release Fourth Quarter and Full Year 2019 Financial Results on Tuesday, February 4, 2020
Jan 13, 2020 05:45AM Kyverna Therapeutics Secures $25 Million Series A Funding from Key Investors and Enters into Strategic Collaboration with Gilead Sciences
Jan 9, 2020 08:31AM Gilead Sciences (GILD) Licenses Portfolio of HIV Antibodies From The Rockefeller University
Jan 9, 2020 08:30AM Gilead Sciences Licenses Portfolio of HIV Antibodies From The Rockefeller University
Jan 9, 2020 07:37AM Scholar Rock Holding Corp. (SRRK) Reports $25M Milestone Payment from Strategic Fibrosis Collaboration with Gilead Sciences (GILD)
Jan 9, 2020 07:30AM Scholar Rock Achieves First Milestone in Strategic Fibrosis Collaboration with Gilead Sciences
Dec 23, 2019 08:01AM Gilead Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020
Dec 20, 2019 08:31AM Gilead Sciences (GILD) Announces China NMPA Approves Vosevi for People With Chronic Hepatitis C Infection Who Require Re-Treatment
Dec 20, 2019 08:30AM China National Medical Products Administration Approves Vosevi® (Sofosbuvir, Velpatasvir and Voxilaprevir) for People With Chronic Hepatitis C Infection Who Require Re-Treatment
Dec 19, 2019 04:30PM Gilead Sciences (GILD) Submits Filgotinib NDA to FDA Under Priority Review for Rheumatoid Arthritis Treatment
Dec 19, 2019 04:30PM Gilead Submits Filgotinib New Drug Application to U.S. Food and Drug Administration Under Priority Review for Rheumatoid Arthritis Treatment
Dec 16, 2019 08:03AM Gilead Sciences (GILD) Announces Topline Results From Phase 2 ATLAS Study in Patients With Bridging Fibrosis and Compensated Cirrhosis Due to NASH
Dec 16, 2019 08:00AM  Gilead Announces Topline Results From Phase 2 ATLAS Study in Patients With Bridging Fibrosis (F3) and Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Dec 11, 2019 04:09PM Gilead Sciences' (GILD) Kite Submits BLA to U.S. Food and Drug Administration for Company’s Second CAR T Cell Therapy
Dec 11, 2019 04:05PM Kite Submits Biologics License Application to U.S. Food and Drug Administration for Company’s Second CAR T Cell Therapy
Dec 11, 2019 08:31AM Kite (GILD), Kiniksa (KNSA) Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta and Mavrilimumab in R/R Large B-Cell Lymphoma
Dec 11, 2019 08:30AM Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma
Dec 11, 2019 08:30AM Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma
Dec 11, 2019 08:30AM Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma
Dec 9, 2019 02:46PM Gilead Sciences' (GILD) Kite Presents Positive Results From Pivotal ZUMA-2 Trial in Relapsed or Refractory Mantle Cell Lymphoma
Dec 9, 2019 02:46PM Gilead Sciences' (GILD) Kite and CIBMTR Present Positive Findings From Real-World Use of Yescarta in Relapsed or Refractory Large B-Cell Lymphoma
Dec 9, 2019 02:45PM Kite Presents Positive Results From Pivotal ZUMA-2 Trial in Relapsed or Refractory Mantle Cell Lymphoma
Dec 9, 2019 02:45PM Kite and the CIBMTR® Present Positive Findings From Real-World Use of Yescarta® (Axicabtagene Ciloleucel) in Relapsed or Refractory Large B-Cell Lymphoma
Dec 7, 2019 02:00PM Kite Announces Long-term Data From ZUMA-1 Showing Approximately Half of Refractory Large B-cell Lymphoma Patients Were Alive Three Years After Yescarta Treatment
Nov 27, 2019 02:16PM National AIDS Memorial Receives $2.4 Million Donation From Gilead Sciences to Support the AIDS Memorial Quilt as It Moves Home to San Francisco
Nov 21, 2019 08:30AM Industry Veterans Appointed to Head the Global Technical Operations and Clinical Development Organizations at Kite
Nov 9, 2019 04:30PM NEW DATA ON FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) DEMONSTRATE DURABLE EFFICACY AND SAFETY PROFILE
Nov 9, 2019 04:30PM New Data on Filgotinib in Rheumatoid Arthritis (RA) Demonstrate Durable Efficacy and Safety Profile
Nov 8, 2019 08:00AM Data Showing Potential for Machine Learning to Advance Understanding of Nonalcoholic Steatohepatitis (NASH) Presented at the Liver Meeting® 2019
Nov 8, 2019 08:00AM Gilead Announces New Data from Viral Hepatitis Research Programs at The Liver Meeting® 2019
Nov 8, 2019 08:00AM Gilead Presents Data on Investigational HIV-1 Capsid Inhibitor GS-6207 as a Potential Component of Long-Acting HIV Therapy
Nov 6, 2019 09:03AM Gilead Sciences' (GILD) Kite to Present New Data From Industry-leading Cell Therapy Portfolio at ASH
Nov 6, 2019 09:00AM Kite to Present New Data From Industry-leading Cell Therapy Portfolio at ASH 2019
Nov 6, 2019 06:56AM Gilead Sciences (GILD) Reports Biktarvy Maintained High Efficacy w/no Cases of Treatment-Emergent Resistance Through 3-Yrs in Ph. 3 HIV Clinical Trials
Nov 6, 2019 06:45AM Gilead Presents 96-week Discover Trial Data Supporting Non-inferior Efficacy and Key Safety Differences of Descovy For PrEP™ Compared With Truvada For PrEP®
Nov 6, 2019 06:45AM Gilead’s Biktarvy Maintained High Efficacy With No Cases of Treatment-Emergent Resistance Through Three Years in Phase 3 HIV Clinical Trials
Oct 31, 2019 04:46PM Gilead Sciences (GILD), Galapagos (GLPG) to Present New Data on Filgotinib at 2019 ACR/ARP Annual Meeting
Oct 31, 2019 04:01PM Gilead and Galapagos to Present New Data on Filgotinib at 2019 ACR/ARP Annual Meeting
Oct 28, 2019 08:05AM Gilead Sciences (GILD), Glympse Bio Report Strategic Collaboration for Use of Biomarker Technology in NASH Clinical Development
Oct 28, 2019 08:00AM Gilead and Glympse Bio Announce Strategic Collaboration for Use of Biomarker Technology in NASH Clinical Development
Oct 24, 2019 04:02PM Gilead Sciences Announces Fourth Quarter 2019 Dividend
Oct 15, 2019 08:30AM Gilead Sciences (GILD) Appoints Andrew Dickinson as CFO
View More Recent Stories View Older Stories